Objective: Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease with similarities to human multiple sclerosis involving peripheral activation of autoreactive T cells which infiltrate the central nervous system and react to self antigens leading to damage. In previous studies, we have demonstrated that treatment with diazepam decreases the incidence and histological signs associated with the disease and diminishes immunological responses. The aim of the present work was to evaluate direct effects of diazepam on isolated T cells involved in immune responses during the development of EAE. Methods: Animals were sensitized with whole myelin to induce EAE and sacrificed during the acute phase of the disease. In mononuclear cells isolated from popliteal lymph nodes, cell viability, apoptosis induction, proliferation and cytokine production were evaluated. Results: Diazepam did not have a toxic or proapoptotic effect on the cells, at least up to the concentration of 25 μM, but proliferation, CD8+ T-cell activation and proinflammatory cytokine production were dose-dependently decreased. Conclusions: Diazepam has a direct inhibitory effect on the proliferation and activation of T lymphocytes isolated from the main lymphoid organ involved in disease onset and this could be one of the mechanisms that contribute to the beneficial effect previously observed with diazepam in vivo during EAE development.

Keywords:
Autoimmunity, Experimental autoimmune encephalomyelitis, Myelin basic protein, Benzodiazepines, T lymphocytes
1.
de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven MA: Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 2003;55:39-50.
2.
Olsen RW, Sieghart W: GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009;56:141-148.
3.
Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008;118:69-86.
4.
Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère J-J, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang M-R, Gavish M: Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006;27:402-409.
5.
Venneti S, Lopresti BJ, Wiley CA: The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol 2006;80:308-322.
6.
Casellas P, Galiegue S, Basile AS: Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 2002;40:475-486.
7.
Descotes G, Mazue G, Richez P: Drug immunotoxicological approaches with some selected medical products: cyclophosphamide, methylprednisolone, betamethasone, cefoxitine, minor tranquillizers. Toxicol Lett 1982;13:129-137.
8.
Zavala F: Benzodiazepines, anxiety and immunity. Pharmacol Ther 1997;75:199-216.
9.
Kalashnikov SV, Kalashnikova EA, Kokarovtseva SN: Immunomodulating effects of tofizopam (Grandaxin) and diazepam in vitro. Mediators Inflamm 2002;11:53-59.
10.
Wei M, Li L, Meng R, Fan Y, Liu Y, Tao L, Liu X, Wu C: Suppressive effect of diazepam on IFN-γ production by human T cells. Int Immunopharmacol 2010;10:267-271.
11.
Schlumpf M, Lichtensteiger W, Ramseier H: Diazepam treatment of pregnant rats differentially affects interleukin-1 and interleukin-2 secretion in their offspring during different phases of postnatal development. Pharmacol Toxicol 1993;73:335-340.
12.
Bento de Lima C, Sakai M, Oliveira Latorre A, de Moraes Moreau RL, Palermo-Neto J: Effects of different doses and schedules of diazepam treatment on lymphocyte parameters in rats. Int Immunopharmacol 2010;10:1335-1343.
13.
Bibolini MJ, Chanaday NL, Báez NS, Degano AL, Monferran CG, Roth GA: Inhibitory role of diazepam in autoimmune inflammation in rats with experimental autoimmune encephalomyelitis. Neuroscience 2011;199:421-428.
14.
Núñez-Iglesias MJ, Novío S, Almeida-Dias A, Freire-Garabal M: Inhibitory effects of alprazolam on the development of acute experimental autoimmune encephalomyelitis in stressed rats. Pharmacol Biochem Behav 2010;97:350-356.
15.
Gilani AA, Dash RP, Jivrajani MN, Thakur SK, Nivsarkar M: Evaluation of GABAergic transmission modulation as a novel functional target for management of multiple sclerosis: exploring inhibitory effect of GABA on glutamate-mediated excitotoxicity. Adv Pharmacol Sci 2014;2014:632376.
16.
Ludwin SK: The pathogenesis of multiple sclerosis: relating human pathology to experimental studies. J Neuropathol Exp Neurol 2006;65:305-318.
17.
Slavin DA, Bucher AE, Degano AL, Soria NW, Roth GA: Time course of biochemical and immunohistological alterations during experimental allergic encephalomyelitis. Neurochem Int 1996;29:597-605.
18.
Vilcaes AA, Furlan G, Roth GA: Inhibition of Ca2+-dependent glutamate release in cerebral cortex synaptosomes of rats with experimental autoimmune encephalomyelitis. J Neurochem 2009;108:881-890.
19.
Cid MP, Vilcaes AA, Rupil LL, Salvatierra NA, Roth GA: Participation of the GABAergic system on the glutamate release of frontal cortex synaptosomes from rats with experimental autoimmune encephalomyelitis. Neuroscience 2011;199:421-428.
20.
Degano AL, Roth GA: Passive transfer of experimental autoimmune encephalomyelitis in Wistar rats: dissociation of clinical symptoms and biochemical alterations. J Neurosci Res 2000;59:283-290.
21.
Xiong Y, Zhang S, Lu J, Sun S, Song B, Xu L, Yang Z, Guan S: Investigation of effects of farrerol on suppression of murine T lymphocyte activation in vitro and in vivo. Int Immunopharmacol 2013;16:313-321.
22.
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods 1995;184:39-51.
23.
Guasconi L, Serradell MC, Masih DT: Fasciola hepatica products induce apoptosis of peritoneal macrophages. Vet Immunol Immunopathol 2012;148:359-363.
24.
Brisslert M, Bokarewa M, Larsson P, Wing K, Collins LV, Tarkowski A: Phenotypic and functional characterization of human CD25+ B cells. Immunology 2006;117:548-557.
25.
Sospedra M, Martin R: Antigen-specific therapies in multiple sclerosis. Int Rev Immunol 2005;24:393-413.
26.
Hill N, Sarvetnick N: Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol 2002;14:791-797.
27.
Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177:566-573.
28.
Kalish RS, Askenase PW: Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 1999;103:192-199.
29.
Ohta N, Ohashi Y, Takayama C, Mashimo T, Fujino Y: Midazolam suppresses maturation of murine dendritic cells and priming of lipopolysaccharide-induced T helper 1-type immune response. Anesthesiology 2011:114:355-362.
30.
Falcón CR, Fernández Hurst N, Cervi LC, Monferran CG, Roth GA: The inhibitory effect of diazepam on induced LPS-dendritic cell activation. LXI Reunión Científica Anual de la Sociedad Argentina de Inmunología (SAI) 2013;86:102.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.